Neomente is developing an AI-powered Clinical Decision Support System (CDSS) to optimize the selection of mental health treatments through personalized, data-driven approaches. Our goal is to revolutionize how mental disorders are diagnosed and treated by offering precision care tailored to each patient’s individual needs.
Transform mental health care with personalized AI.
Neomente revolutionizes the diagnosis and treatment of mental disorders by combining genetics, clinical analysis and the power of AI.
Give your patients the right treatment from the start. Up to 60% of people fail to respond to conventional mental health treatments. Neomente changes that from the first try, combining genetic biomarkers, clinical data and blood tests in a single AI-powered platform.
Play Demo
Length (1:58 Min)
Experts agree: Neomente is the future of mental health. 
Always have patient information at your fingertips.
With Neomente, each practitioner has access to a comprehensive and personalized patient record. From genetic biomarkers to clinical history, everything is in one place. This approach enables detailed and dynamic follow-up, ensuring that treatment is always optimized based on the latest available data.
Key features
- Analysis of genetic and metabolic biomarkers.
- Complete and updated clinical history.
- Artificial intelligence-assisted recommendations.
- Data integration for a 360° view of the patient.
Benefits:
- More accurate and faster clinical decisions.
- Total treatment personalization.
- Improved adherence to international mental health protocols.
Frequently Asked Questions (FAQ)
What problem does Neomente address?
Neomente tackles the challenges of traditional mental health treatment selection methods, which often rely on trial and error. This can result in long delays in finding effective therapies and contributes to up to 50% of patients not responding to their first prescribed medication. Neomente aims to improve these outcomes by using AI to personalize treatment selection—factoring in each patient’s unique genetic makeup, blood biomarkers, and clinical data.
What is the validation of the Neomente approach?
Preliminary results of Neomente’s CDSS for depression have shown promising results, including improvements in response and remission rates. To further validate our technology, we are conducting clinical trials in Buenos Aires, and initial results have been presented at international congresses, such as the European Congress of Neuropsychopharmacology (ECNP) and the World Congress of Psychiatry (WPA).
